PMID- 28286162
OWN - NLM
STAT- MEDLINE
DCOM- 20170809
LR  - 20171212
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 102
IP  - 2
DP  - 2017 Apr
TI  - Gli1 expression in cancer stem-like cells predicts poor prognosis in patients 
      with lung squamous cell carcinoma.
PG  - 347-353
LID - S0014-4800(17)30017-5 [pii]
LID - 10.1016/j.yexmp.2017.03.004 [doi]
AB  - PURPOSE: Glioma-associated oncogene homolog 1 (Gli1) is involved in cancer stem 
      cell (CSC) maintenance in various tumors; however, its expression and clinical 
      significance in lung squamous cell carcinoma (LSCC) has not been reported. In 
      this study, we aimed to reveal the clinical significance of Gli1 in LSCC and 
      investigate the potential of Gli1 as a CSC marker by comparing its expression 
      with that of other stemness-related genes in LSCC. METHODS: We assessed the 
      expressions of Gli1, LSD1, CD44, Sox9 and Sox2 by immunohistochemistry in the 
      tissue specimens obtained from 101 patients with LSCC. The relationship of Gli1 
      expression with clinicopathological parameters and cell-cycle regulating genes 
      was investigated. RESULTS: Gli1 expression was significantly correlated with T 
      stage (P<0.001), lymph node metastasis (P=0.002), and clinical stage (P=0.005) of 
      LSCC. The Kaplan-Meier survival analysis revealed that the expression of Gli1 in 
      LSCC was all significantly associated with poor overall survival (OS: P=0.005). 
      Cox regression analysis further confirmed that Gli1 is a prognostic marker of 
      unfavorable clinical outcome of LSCC. Gli1 expression was significantly 
      correlated with the expression of stemness-related genes such as LSD1 (P=0.009) 
      and CD44 (P<0.001), but not with those of Sox2 and Sox9. However, Gli1 expression 
      was associated with the expression of hypoxia-inducible factors1alpha (HIF1alpha; 
      P<0.001) and Cyclin D1 (P=0.002), respectively. In additionally, microvessel 
      density (MVD) was significantly higher in Gli1-positive LSCC than in the negative 
      LSCC (P=0.026). CONCLUSIONS: Our results suggest that Gli1 may be a potential 
      LSCC stem cell marker and an independent indicator of poor prognosis for patients 
      with LSCC.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Cui, Yan
AU  - Cui Y
AD  - Department of Oncology, Affiliated Hospital of Yanbian University, Yanji, China.
FAU - Cui, Chun-Ai
AU  - Cui CA
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Yang, Zhao-Ting
AU  - Yang ZT
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Ni, Wei-Dong
AU  - Ni WD
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China.
FAU - Jin, Yu
AU  - Jin Y
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China. Electronic address: jinyu@ybu.edu.cn.
FAU - Xuan, Yan-Hua
AU  - Xuan YH
AD  - Key Laboratory of Natural Resources of the Changbai Mountain and Functional 
      Molecules, Ministry of Education, Yanbian University, Yanji 133002, China; 
      Institute for Regenerative Medicine, Yanbian University College of Medicine, 
      Yanji 133002, China. Electronic address: xuanyh1@ybu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170309
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCND1 protein, human)
RN  - 0 (CD44 protein, human)
RN  - 0 (GLI1 protein, human)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (SOX2 protein, human)
RN  - 0 (SOX9 Transcription Factor)
RN  - 0 (SOX9 protein, human)
RN  - 0 (SOXB1 Transcription Factors)
RN  - 0 (Zinc Finger Protein GLI1)
RN  - 136601-57-5 (Cyclin D1)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.5.- (KDM1A protein, human)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics
MH  - Cyclin D1/genetics/metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histone Demethylases/genetics/metabolism
MH  - Humans
MH  - Hyaluronan Receptors/genetics/metabolism
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/diagnosis/*genetics
MH  - Male
MH  - Neoplastic Stem Cells/*metabolism
MH  - Prognosis
MH  - SOX9 Transcription Factor/genetics/metabolism
MH  - SOXB1 Transcription Factors/genetics/metabolism
MH  - Zinc Finger Protein GLI1/genetics/*metabolism
OTO - NOTNLM
OT  - Cancer stem cell
OT  - Gli1
OT  - Lung squamous cell carcinoma
OT  - Prognosis
EDAT- 2017/03/14 06:00
MHDA- 2017/08/10 06:00
CRDT- 2017/03/14 06:00
PHST- 2017/01/16 00:00 [received]
PHST- 2017/03/03 00:00 [revised]
PHST- 2017/03/08 00:00 [accepted]
PHST- 2017/03/14 06:00 [pubmed]
PHST- 2017/08/10 06:00 [medline]
PHST- 2017/03/14 06:00 [entrez]
AID - S0014-4800(17)30017-5 [pii]
AID - 10.1016/j.yexmp.2017.03.004 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2017 Apr;102(2):347-353. doi: 10.1016/j.yexmp.2017.03.004. Epub 
      2017 Mar 9.